Alaunos Therapeutics Inc.

NASDAQ: TCRT · Real-Time Price · USD
2.27
-0.13 (-5.42%)
At close: Aug 15, 2025, 3:59 PM
2.20
-2.87%
After-hours: Aug 15, 2025, 07:31 PM EDT

Alaunos Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
10K 9K 6K 6K 6K 5K 15K 2.93M 2.92M 2.92M 2.91M 398K 398K 398K 398K n/a n/a
Cost of Revenue
1K 3K 244K 1.31M 2.84M 3.53M 4.1M 3.73M 2.88M 2.87M 2.77M 2.08M 2.07M 1.92M 1.22M 1.22M 540K
Gross Profit
9K 6K -238K -1.3M -2.83M -3.53M -4.08M -799K 45K 52K 141K -1.68M -1.68M -1.53M -821K -1.22M -540K
Operating Income
-4.16M -4.81M -7.42M -14.93M -21.75M -29.68M -34.84M -34.44M -35.69M -35.1M -37.63M -51.66M -65.07M -77.55M -89.27M -87.3M -83.26M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-4.07M -4.68M -11.78M -19.13M -26.77M -35.14M -36.46M -36.83M -37.99M -37.73M -40.36M -54.24M -66.98M -78.75M -89.73M -87.31M -83.24M
Net Income
-4.07M -4.68M -11.78M -19.13M -26.77M -34.44M -36.4M -37.36M -38.39M -39.52M -41.52M -54.81M -67.69M -78.75M -89.73M -87.31M -83.24M
Selling & General & Admin
3.59M 4.46M 5.8M 8.37M 10.43M 11.98M 12.72M 12.42M 12.8M 13.14M 12.31M 17.2M 22.84M 27.56M 34.27M 32.45M 29.94M
Research & Development
584K 363K 1.38M 4.89M 9.9M 16.28M 20.95M 25.19M 25.94M 25.02M 27.63M 34.26M 41.89M 49.64M 55.4M 54.84M 53.33M
Other Expenses
n/a n/a n/a 188K 465K 942K 1.19M 1.26M 1.02M 525K -469K -716K -788K -759K -13K -14K 27K
Operating Expenses
4.17M 4.82M 7.18M 13.27M 20.33M 28.26M 33.67M 37.61M 38.74M 38.16M 39.93M 51.45M 64.72M 77.2M 89.67M 87.3M 83.26M
Interest Expense
n/a n/a n/a n/a 1.07M 1.92M 2.81M 3.65M 3.32M 3.15M 3.01M 2.6M 1.89M 1.21M 468K 31K n/a
Selling & Marketing Expenses
n/a -2K -243K -243K -243K -241K -6.79M -6.79M -6.79M -6.79M -25.47M -25.47M -25.47M -25.47M -18.86M -18.86M -18.86M
Cost & Expenses
4.17M 4.82M 7.42M 13.51M 20.57M 28.5M 33.67M 37.61M 38.74M 38.16M 39.93M 51.45M 64.72M 77.2M 89.67M 87.3M 83.26M
Income Tax Expense
n/a n/a -837K -837K -837K -1.53M -58K 529K 396K 1.79M 1.88M 1.29M 1.46M 745K 20K 14K -27K
Shares Outstanding (Basic)
1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.49M 1.43M 1.43M 1.43M 1.43M 1.43M 1.43M 1.43M
Shares Outstanding (Diluted)
1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M 1.49M 1.43M 1.43M 1.43M 1.43M 1.43M 1.43M 1.43M
EPS (Basic)
-2.54 -2.92 -7.36 -11.96 -16.74 -21.54 -23.22 -24.5 -25.85 -27.32 -28.98 -38.29 -47.31 -55.1 -62.89 -61.32 -58.57
EPS (Diluted)
-2.54 -2.92 -7.36 -11.96 -16.74 -21.54 -23.22 -24.5 -25.85 -27.32 -28.98 -38.29 -47.31 -55.1 -62.89 -61.32 -58.57
EBITDA
-4.07M -4.68M -11.54M -17.82M -23.7M -30.52M -30.38M -30.29M -31.79M -31.71M -34.59M -48.89M -62.37M -74.97M -86.97M -85.35M -81.71M
EBIT
-4.07M -4.68M -11.78M -19.13M -25.71M -33.22M -33.65M -33.18M -34.67M -34.58M -37.38M -51.66M -65.14M -77.58M -89.29M -87.32M -83.25M
Depreciation & Amortization
23K 25K 267K 1.31M 2.84M 3.53M 4.1M 3.73M 2.88M 2.87M 2.77M 2.75M 2.75M 2.6M 2.31M 1.96M 1.53M